At iBio, we are using our Discovery Platform to tackle complex and challenging drug targets, with the goal of developing safer and more effective immunotherapies for difficult-to-treat cancers. We envision a world where drug discovery is not left to chance but guided by artificial intelligence to make therapeutic development smarter, more precise, and ultimately faster. With our Discovery Platform, we are pursuing hard-to-drug targets with greater potential and less competition. We have nine immuno-oncology candidates in our pipeline, including those for the potential treatment of solid tumors, glioblastoma, and head and neck cancers. An essential challenge to developing antibody drugs is that traditional discovery technologies employ a high degree of randomness. Creating an antibody with a set of desired qualities requires repeated attempts until the optimal result is achieved, often by chance. While this approach has yielded valuable therapeutics in the past, that outcome is rare, with fewer than 1 in 1,000 targets ever reaching the clinic. Traditional antibody development methods are time-consuming and costly, and we believe ultimately produce fewer potentially life-saving drugs than possible. We believe that our Discovery Platform offers the precision required to solve this problem while also identifying the most challenging targets.
View Top Employees from iBio, Inc.Website | http://www.ibioinc.com |
Ticker | IBIO |
Revenue | $2 million |
Employees | 90 (90 on RocketReach) |
Founded | 2008 |
Address | 8800 HSC Pkwy, Bryan, Texas 77807, US |
Phone | (979) 446-0027 |
Fax | (302) 356-1173 |
Technologies |
JavaScript,
HTML,
PHP
+39 more
(view full list)
|
Industry | Pharmaceuticals, Biotechnology Research, Biotechnology, Plant-based iBioLaunchâ„¢ Platform Technology, Healthcare, Science and Engineering, Therapeutic proteins, Genetics, Vaccines, Health Care, Monoclonal antibodies, Robotics, Hardware, Software, Therapeutics |
Web Rank | 12 Million |
Keywords | Ibio, "Plant-Made Pharmaceutical", Ibio College Station, Ibio Inc |
Competitors | Chemstar Products, Molecular Medicine BioServices, Premas Biotech, VBI Vaccines Inc., Ventria Bioscience Inc |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 541711 Companies, NAICS Code 32541 Companies, NAICS Code 325414 Companies, NAICS Code 3254 Companies, NAICS Code 325 Companies, NAICS Code 54171 Companies, NAICS Code 32 Companies, NAICS Code 5417 Companies, NAICS Code 54 Companies, NAICS Code 541 Companies |
Looking for a particular iBio, Inc. employee's phone or email?
The iBio, Inc. annual revenue was $2 million in 2024.
Mike Jenkins is the Vice President Operations of iBio, Inc..
90 people are employed at iBio, Inc..
iBio, Inc. is based in Bryan, Texas.
The NAICS codes for iBio, Inc. are [541711, 32541, 325414, 3254, 325, 54171, 32, 5417, 54, 541].
The SIC codes for iBio, Inc. are [28, 283].